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Abstract:  
Cardiovascular disease (CVD) is a leading cause of mortality and morbidity in developed 
countries. CVD is produced by atherosclerotic lesions that reduce arterial lumen size through 
plaque formation and arterial thickening. This decreases blood flow to the heart and frequently 
manifests in severe hemodynamic complications like myocardial infarction or angina pectoris. A 
drug delivery system (DDS) is a clinical methodology (formulation or device) which enables the 
introduction of a therapeutic substance into the body and improves its efficacy and safety by 
controlling the rate, time, and place of release of drugs in the body. Drug delivery technologies 
modify drug release profile, absorption, distribution and elimination for the benefit of improving 
product effectiveness and patient convenience and compliance. The review explores extensively 
hemodynamic aspects of the cardiovascular system and diseases which can be treated via nano-
drug delivery with a comprehensive overview of research efforts in these areas.  Nanomedicine is 
an expeditiously growing science in which biomaterials (drugs) engineered at the nanoscale are 
implemented to enhance therapeutic performance and improve patient treatments. Among the 
many other diverse applications of nanomaterials in medicine (e.g. bio-UIRtribology, tissue repair, 
orthopaedic implants etc), nano-drug delivery systems have emerged as among the most 
promising. This technology has evolved into a significant platform for delivering successfully 
remedial agents to diseased sites with substantially greater target control, precision and 
sophistication. By greatly increasing site specificity, lowering toxicity and target-oriented 
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delivery, nanotechnological drug delivery (“nano-pharmacodynamics”) has consistently achieved 
very impressive consistency, benefits and has aided massively in the fight against potentially lethal 
haemotological diseases. Recently, nanomedicine has embraced an even wider range of 
applications including the administration of chemotherapeutic agents, biological agents, diabetes 
regulation, sterilization, cancer and tumour inhibition, rheumatic fever mitigation etc. The current 
review presents a comprehensive appraisal of nano-drug delivery systems, simulation with 
engineering methods, types of nanodrugs and their effectiveness. The excellent targeting properties 
attainable with magnetic nanoparticles as engineering pharmacodynamic agents, in particular, 
offers huge potential in the treatment of many complex hemodynamic disorders. Furthermore, the 
present review summarizes the efficiency of drug carrier nanoparticles in mitigating the adverse 
effects of stenosed blood vessels and outlines other future potential uses for nano-drugs in 
biomedical applications.   
Keywords:  Drug Delivery System; Nanoparticles; Blood Flow; Cardiovascular Diseases; Nano-
Magnetic Drug Delivery; Nanomedicine; Arterial Lumen. 
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Hemodynamics has an integral role in the formation and evolution of cardiovascular diseases. 
Accumulation of macrophage white blood cells, low-density lipoproteins (LDL) and deposition of 
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cholesterol to the arterial wall of blood vessels results in a hardening of the arteries and reduction 
in the cross-sectional area of the blood vessel thereby leading to cardiovascular diseases. 
Simulation of blood flow has been widely used in recent decades for better understanding the 
symptomatic spectrum of various diseases, in order to improve already existing clinical treatments 
or to develop new therapeutic techniques. The characteristics of the blood flow in an artery can be 
changed significantly by arterial disease and important examples of geometric modifications to the 
arterial structure are aneurysms and stenoses. Blood vessels are tapered by the growth of 
atherosclerotic plaques that bulge into the lumen, resulting in stenosed blood vessels. Thus, the 
development of a stenosis can lead to severe circulatory and arterial disorders. In the recent past a 
considerable number of theoretical and experimental investigations related to blood flow in arteries 
in the presence of a stenosis have been reported with various perspectives in the area of arterial 
biomechanics depending upon the objectivity of the problems of the life sciences. Human blood is 
a heterogeneous multiphase suspension of blood cells (red blood, white blood, platelets) in plasma, 
which constitutes about 55% of total blood volume and is composed of mostly water, dissipated 
proteins, mineral ions, clotting factors, hormones and blood cells [1]. It has been pointed out that 
the plasma behaves as a Newtonian fluid [2]; however, whole blood exhibits non-Newtonian fluid 
nature [3]. For shear rate larger than 100 s-1, blood exhibits a Newtonian nature, and this arises in 
for example, large arteries, veins and in large cavities. However, for shear rate less than 100 s-1, 
blood behaviour is non-Newtonian i.e. hemo-rheological.  
 
Blood component Per microliter Size (µm) Percentage 
Red blood cell 4.1-5.1 x 106 7-8 97 
White blood cell       Neutrophils 
(4-10 x 103)             Lymphocytes 
                                 Eosinophils 
                                 Monocytes 
                                 Basophils 
 
62% of WBC 
30% of WBC 
2.3% of WBC 
5.3% of WBC 







Platelet 1.5-4.5 x 105 3 1 




Across a wide range of cardiovascular diseases, the best outcome depends on the ability to 
successfully direct drugs towards a specific diseased zone. Despite intense research and 
developments in drug delivery, present-day pharmacological formulations still leave the drug 
incapable of precisely localizing en mass at sites of interest. The drug molecules diffuse and spread 
in many cases randomly throughout the body, resulting in undesirable side effects and a reduction 
in the active response of proper doses. In recent years a new branch of fluid dynamics, focused on 
engineering fluids at the nanoscale, has emerged - nanofluid dynamics. Nanofluids have had a 
significant impact in improving miscellaneous applications in energy systems, industrial 
processes, transport, environmental and biomedical sciences. 
 
Figure 1: A normal artery versus diseased artery [88] 
 
1.1 Clinical Research Importance 
 According to World health organization (WHO) report 2017 [4], Cardiovascular diseases (CVDs) 
are the first cause of deaths worldwide. Annually more people die because of CVDs in comparison 
with any other diseases. In 2016, almost 17.9 million deaths were documented due to CVDs, which 
corresponds to approximately 31% of total deaths. In addition, 85% of these deaths are due to 
strokes and heart attacks. The WHO report also emphasizes that low and middle-income countries 
are more prone to cardiovascular diseases as almost three quarters of total CVDs deaths arose in 
these countries. Out of 17 million premature deaths attributable to non-communicable diseases in 




Figure 2: % of total deaths due to each aspect of cardiovascular diseases in India, 2016 [5] 
In 2016, cardiovascular diseases contributed 28.1% of the total deaths in India. For CVDs, the 
dominating risk factors include high systolic blood pressure, air pollution, high cholesterol, 
dietary risks, tobacco use and high body mass index.  The main causes under cardiovascular 
diseases with the percentage of death rates are presented in Figure 2. 
 
1.2 Nanofluids 
Conventional fluids (air, water, oils etc) in industrial applications exhibit excellent lubrication 
properties; however, they have poor thermal characteristics which severely restrain their use. 
Nowadays, many researchers have been focused on developing techniques to increase heat transfer 
rates of conventional fluids. Experimentally it was found that the addition of small-sized solid 
particles in the base fluid can greatly enhance the thermo-physical properties. In 1995, Choi [6] 
coined a new term “nanofluid”, which is defined as a colloidal suspension of nanometer-sized 
particles (1-100nm) in a base fluid. These nanoparticles can be oxide, carbide, metallic, non-
metallic, carbonic, hybrid and even more liquid droplets. The base fluid includes water, mineral 
oil, ethylene glycol or refrigerants. It has been shown that the inclusion of nanoparticles (termed 
“doping”) in base fluids increases the thermal conductivity remarkably and this contributes 
principally to the improved thermal performance of nanofluids. The nanoparticles employed in 




1.2.1 Thermophysical Properties 
In comparison with base fluids, nanofluids are formed have significantly different thermophysical 
properties such as thermal conductivity, viscosity, density and specific heat capacity. 
(A) Density: With the help of the properties of both base fluid and nanoparticles, the effective 
density of nanofluid is numerically calculated by [9] as: 
                                                    𝜌𝑛𝑓 = (1 − 𝜑)𝜌𝑓 + 𝜑𝜌𝑠                                                  .........(1) 
Where 𝜌𝑓 and 𝜌𝑠 is a density of the base fluid and nanoparticle respectively and 𝜑 is nanoparticle 
volume fraction.  
(B) Specific Heat Capacity: Effective heat capacity can be computed using the following equation 
as reported in [9] as- 
                                         (𝐶𝑝)𝑛𝑓 = (1 − 𝜑)(𝐶𝑝)𝑓 + 𝜑(𝐶𝑃)𝑠                                                 ..........(2) 
Some other approaches have also been suggested regarding the heat capacity concept [10], for 
example- 
                                       (𝜌𝐶𝑝)𝑛𝑓 = (1 − 𝜑)(𝜌𝐶𝑝)𝑓 + 𝜑(𝜌𝐶𝑃)𝑠                                        ..............(3) 
(C) Viscosity: For the effective viscosity of a nanofluid, many models have been suggested by 
researchers considering the nanoparticle suspension in the base fluid. The first model for a 
suspension was suggested by Einstein [11] in 1906 and the derived equation is:  
                                                  𝜇𝑛𝑓 = (1 + 2.5𝜑)𝜇𝑓                                                    ...............(4) 
As the model given by Einstein is restricted to spherical particles only, some other models also 
have been proposed by many researchers for non-spherical particles. A very important model was 
proposed by Brinkman [12] in 1952, which is- 
                                                   𝜇𝑛𝑓 =
𝜇𝑓
(1−𝜑)2.5
                                                          ............. (5) 
(D) Thermal Conductivity: Hamilton and Crosser [13] presented a robust model for the thermal 
conductivity of solid-liquid mixtures of non-spherical particles, which is given below as: 






                                           ........... (6) 
Where 𝑘𝑠 and 𝑘𝑓 are the thermal conductivity of nanoparticles and base fluid, respectively, n is 
an empirical shape factor, calculated as 𝑛 =
3
𝜓





Generally, the rate of heat exchange in thermal systems is enhanced by using a nanofluid, due to 
the superior thermal conductivity over the conventional fluid. Therefore, by using nanofluids to 
enhance the heat transfer rate, the size of a thermal system can be optimized by transferring a 
specific value of heat which makes the system more compact. Relative to microfluids, nanofluids 
possess a higher stability and better potential to increase the heat conduction [14]. In many heating 
and cooling applications, nanofluids are superseding conventional fluids. Nanofluids can be used 
in car radiators, boilers, cooling of electronic equipment, solar collector systems, refrigerators, 
pharmacological drug delivery, sterilization, fuel cells, lubrication of components, aerospace 
coatings and fuels, enhanced oil recovery techniques and liquid based heat exchangers. Figure 3 
gives an overview of different applications of nanofluids. 
 
Figure 3: Applications of Nanofluids [15] 
 
2. Drug Delivery Systems 
2.1 Drug Designing and Drug Delivery Process 
For many years, it has been found that the delivery of therapeutic compound to a target area is a 
primary obstacle in the treatment of several diseases. Limited effectiveness, poor bioavailability 
and solubility and also toxicity are major disadvantages of traditional drugs. To overcome these 
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limitations and drawbacks, controlled drug delivery has been proposed and developed. For drug 
delivery, there are essentially two aims: firstly, to reduce the drug side effects by specifically 
targeting the desired organ and secondly to avoid overdosing or under-dosing cycles by controlled 
release of the drug [16]. A drug delivery system (DDS) is a formulation or a device that enables 
the introduction of a therapeutic substance into the body and improves its efficacy and safety by 
controlling the rate, time, and place of release of drugs in the body. In particular, a DDS constitutes 
precision-engineered biotechnology for the controlled release and/or targeted delivery of 
therapeutic handler. Controlled drug delivery systems are designed in a way that the drug is 
transported to the target region with simultaneous avoidance (or at least reduction) in any 
undesired influence on vital tissues and unwanted side effects [17]. This delivery system defends 
the drug from expeditious deterioration and increases the drug concentration in targeted tissues, 
which results in the benefit of requiring lower doses of drugs. This therapy is found to be important 
when there is variation between a dose of drug and its toxic effects in body. To further improve 
therapeutic effects and reduce the undesirable side (toxic) effects, continuous development and 
refinement of suitable drug vehicles is a growing field in biomedical and pharmaceutical 
engineering.   
 
2.2 Nano-based Drug Delivery Systems 
In drug delivery systems, using large size of materials or carriers poses major challenges including 
poor bioavailability and solubility, issue with target specificity, in vivo stability and tonic 
effectiveness with probable side effects. Therefore, in advanced biomedicine, nanotechnology 
offers substantial promise in drug formulations which control drug release and deliver the drug 
with more specificity. Nanomaterials are materials engineered in the range between 1 and 100 nm. 
Nanoparticles have been extensively implemented in recent years in many sub-branches of 
biomedicine including drug delivery, tissue engineering and biosensors [18, 19]. Nanoparticles are 
usually small sized nanospheres; hence in comparison to larger particles they can move more freely 
in the human body. Nowadays nanomedicine has matured into a major area of biomedicine since 
nano-designed delivery agents can be embedded in therapeutic drugs and targeted drug delivery 
can be achieved with controlled release [20]. The first generation of nanoparticle-based therapy 
has been based on lipids systems like micelles and liposomes [21], which can contain inorganic 
nanoparticles like silver, gold or metallic. Nanostructures stay in the circulatory system for 
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prolonged duration and allow the release of drugs at fixed doses and rates, which cause less plasma 
fluctuations leading to minimized side effects [22].  
 
Figure 4: Passive targeting vs Active targeting [23] 
 
In drug delivery using nanomaterials the selection of a particular nanoparticle, is based, on the 
desired physical and chemical properties of the intended nano-drugs. Two mechanisms are known 
via which nano-engineered pharmacological agents deliver: self-delivery and passive. In the latter, 
drugs are encapsulated in the inner cavity of nanostructure and when the nanostructured drug is 
targeted to a particular region the required amount of drug is then released. In the former, the drugs 
required to be released are directly attached to the carrier nanostructure for easy delivery. In the 
self-delivery approach, the timing of release is a crucial aspect since failure in this regard may 
result in the drug not reaching the targeted site [24]. In drug delivery systems, targeting of drugs 
using nano formulation is also classified into active and passive targeting.  In passive targeting, 
the prepared drug carrier circulates in the blood flow and is driven to the targeted site by binding 
which is strongly influenced by properties like temperature, pH, molecular shape and nanoparticle 
dimensions. In active targeting, antibodies and peptides are coupled with systems to the surface of 
the nanocarriers by different conjugation chemistries. Therefore, nanotechnology provides various 
benefits in treating human diseases with improved site specificity of drugs and more precise 




2.2.1 Nano-Drug Designing and Nano-Drug Delivery Process 
With the progression of drug delivery systems and design, to boost the drug specificity and 
diagnostic accuracy, various conventional methods have been reviewed and many therapeutic 
procedures have been suggested. In light of this, new robust ways of administrating the drug have 
been rigorously examined, which are focused on reducing the side effects by increasing their 
bioavailability in the organ so that controlled or targeted delivery, can be achieved [25]. With 
reference to this, drug design is a critical aspect that characterizes the compatibility of the principal 
drug in the context of a specific biological target. Several studies have been found related to this 
which focuses on the design of different particles and the importance of distinctive mechanisms of 
drug release [26]. Each drug delivery system has its own physical, morphological and physical 
properties and possesses unique compatibility for various drugs polarities through physical and 
chemical interactions. For understanding drug delivery profiles, an appreciation of some other 
parameters including the compositions of nanocarriers (e.g. inorganic, organic etc) and the state in 
which drugs are mixed with them (matrix system or core shell system) is also essential [27]. 
Release of drugs in nanocarriers is represented by different mechanisms which include diffusion, 
stimuli-sensitive, solvent and chemical reaction [28, 29], as depicted in figure 2.  
 




By using external factors (e.g. heat, light, ultrasound, magnetism [30], pH), stimuli-responsive 
nanocarriers have exhibited the capability to control the drug release profile, which further may 
enhance the precision of targeting and allow the better control of dose. To stimulate the controlled 
release, superparamagnetic iron oxide nanoparticles are mixed with lipids [31] or polymeric 
nanocarriers using an external magnetic field. In addition, Chen et al. [33] synthesized gold/ 
ferrous oxide polymer nanoparticles for deployment in chemo-photo-thermal therapy. Such hybrid 
nanocarriers are one of the most promising tools available currently in nanomedicine as a mixture 
of different systems having different properties can be engineered into a single system, which 
improves the diagnostic and therapeutic effectiveness in ever-widening applications. 
 
2.3 Nanoparticles Used in Drug Delivery 
In drug delivery systems, various bio-polymeric materials are being increasingly utilized. The 
efficacy of these nanomaterials varies depending on the size, shape and other physical or chemical 
properties. These materials with their associated characteristics fall into several categories:  
Liposomes: This is one of the most studied drug carrier systems which is used in the 
pharmaceutical industry for the transporatation of different molecules. They were discovered in 
1960 by British biophysicist, Alec Bangham. Liposomes are usually of spherical form in the 50-
450 nm size range and composed of steroids and phospholipids [34]. As the membrane structure 
of liposomes is similar to cell membranes and they allow incorporation of drug in cells, therefore 
they are considered as a more suitable pharmacokinetic delivery vehicle [34]. It has been proved 
that liposomes are biodegradable and biocompatible, that they make therapeutic compounds  more 
stable and can be used with hydrophobic and hydrophilic drugs. One significant point about 
liposomes is that the drugs encapsulated within them are not bio-available until the vesicles are 
released, hence to increase drug bioavailability, their accumulation in a particular region is 
important [32].  
Polymeric micelles: These are formed when polymeric molecules or amphiphilic surfactants 
promptly mix in aqueous solution to form a core shell structure. The inner cavity of micelles is 
hydrophobic (water-hating), which is surrounded by a shell of hydrophilic (water-loving) 
polymers, like polyethylene glycol (PEG) [32]. These are under 100 nm in size and have a narrow 
distribution to avoid fast renal excretion, thus permitting their accumulation through the enhanced 
permeability and retention (EPR) effect in tumor tissues. Drugs are encapsulated within micelles 
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by three different methods i.e. the solvent evaporation process, dialysis process and direct 
dissolution process. These nanostructures pose strong potential in hydrophobic drug delivery 
because their interior core structure allows the absorption of drugs which results in enhancement 
of bioavailability and stability [35]. 
Dendrimers: Dendrimers are three-dimensional, highly bifurcated and mono-dispersed tree-like 
structures. The chemical composition and molecular weight of dendrimers can be controlled more 
precisely in comparison to linear polymers, which makes it comparatively easy to predict their 
biocompatibility [36]. Dendrimers have been developed for oral, pulmonary, transdermal, ocular 
(eye) and targeted delivery [37]. There are three different mechanisms through which drug loading 
is performed in dendrimers: simple encapsulation, covalent conjugation and electro-static 
interaction.  
Inorganic nanoparticles: These nanoparticles include silver, gold, silica etc., which have emerged 
as a very promising tool in therapeutics since they provide a useful complement to more 
conventional delivery vehicles. They possess many beneficial characteristics such as easy 
synthesis, well-established surface functionalization, low toxicity , large surface area and better 
stability all of which contribute towards providing inorganic nanoparticles with unique features 
which are ideal for enabling new delivery strategies. Kong et al. [38] have described in detail how 
drugs can be encapsulated with gold nanoparticle surfaces via covalent bonding or physical 
absorption and through stimuli-responsive or light activation, they can deliver and control the 
release of these nano-engineered drugs. 
Metallic Nanoparticles: In recent years, the use of metallic nanoparticles has expanded very 
rapidly in different medical applications including bioimaging, targeted drug delivery, 
orthopedics, biosensors and hyperthermia [39]. These nanoparticles are particularly useful in 
thermal therapy and targeting. Conventional methods of heating a tissue by microwave (masers) 
or laser light, also unfortunately destroy the healthy tissue surrounding the tumor. However 
targeted magnetic particles constitute a more productive strategy for localized heating of diseased 
cells. The most studied metallic nanoparticles are silver, copper and gold; however there is a 
growing interest in the use of alternative metallic nanoparticles such as platium, zinc oxide and 





Figure 6 : Types of Nanoparticles [40] 
 
Nanocrystals: Nanocrystals are uniform in size distribution within the 1000 nm range. They are 
stabilized by using polymeric surfactants/stabilizers and are 100% drug without any carrier 
molecule attached to them and are stable in aqueous dispersions. Nanocrystals are synthesized by 
top-bottom and bottom-top approaches. Nanocrystals support the absorption of the drug in the 
human circulatory system by several mechanisms which include enhancement of solubility and 
suspension rate [41].  
Carbon-based Nanomaterials: These have attracted special interest due to their suitability for 
surface functionalizing in for example the grafting of peptides, proteins and nucleic acids. For drug 
delivery applications, carbon nanotubes, fullerence and nanodiamonds  have been broadly used. 
Single wall nanotube, multiwall nanotubes and fullerences feature special dimensions, geometry 
and surface characteristics, which make them applealing for drug carrier delivery.  
 
2.4 Nano-Magnetic Drug Delivery  
Nowadays, among the most attractive and powerful strategies for pharmacological drug delivery 
in affected site is the magnetic targeted drug delivery system (MTDDS). In comparison with 
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conventional methods, MTDDS are fast-acting and highly efficient and owing to their capacity in 
reducing toxicity and other adverse side effects, they are becoming more popular in biomedicine 
[42]. Magnetic materials are of 6 types, among which superparamagnetic materials are the most 
attractive for magnetic drug delivery. In this targeting, a drug is bound to a magnetic compound 
and slowly and sytematically introduced into the body, whereupon via  an extra-corporeal 
magnetic field, it is directed to the target site. Depending on the specific application, the 
nanoparticles are then released from the drug by diffusion or any other mechanism. For designing 
MTDDS, a variety of factors including magnetic properties, strength of magnetic field, size and 
drug loading capacity play a major role.  
 
Figure 7 : MNPs with various shells [43] 
To improve the efficiency of magnetic targeted drug delivery systems, composite designs of  
nanoparticles have been explored (hybrid systems). Biomedical applications of magnetic nano 
particles (MNPs) are classified according to their application: in vivo or in vitro. In vivo 
applications involve therapeutics and diagnostics while in vitro applications relate to diagnostic 
usage (seperation/selection). MNPs  are widely used in cell and macromolecule seperation, 
targeted drug delivery, electromagnetic hyperthermia, magnetic resonance imaging (MRI) and 
gene therapy. However the targeting properties of MNPs make them particularly appropriate for  
drug delivery systems [44].  Key characteristics of magnetic nanoparticles are that they can be: (a) 
projected in place by using of magnetic field (b) visualized (c) heated in the presence of magnetic 
field to generate drug release. To maximize these properties, various functional modification has 
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been done in MNPs using polymers, liposomes and silica [45]. To get the best results in drug 
delivery, MNPs must have peculiar properties such as monodispersity, stability, biocompatibility 
and superparamagnetism. Superparamagnetism is a necessary property during drug delivery since 
it is allows the avoidance of agglomeration (a clustering phenomenon which further produces 
embolisms in blood vessels) [46]. The Food and Drug Administration (FDA) have approved the 
use of iron oxides (or particular, magnetite) and confirmed that they are totally safe for humans 
[47].  
 
3. Nano-based Drug Delivery For Cardovascular Diseases 
According to the World Health Organization (WHO) report given in 2017, cardiovascular diseases 
(CVDs) are the leading cause of deaths in world. The data shows that 17.7 million deaths occurred 
up to 2015 and a further 23.6 million are projected to occur up to 2030 [5]. The term cardiovascular 
disease encompasses, but is not restricted to coronary heart disease, thrombosis and pulmonary 
embolism etc. All other WHO data corresponds to ischemia and tissue deaths. Heart failure is a 
clinical disease, having symptoms of fatigue and breathlessness and these symptoms are a result 
of the reduced quality of cardiac functionality [48]. The current statistics emphasize the urgent 
requirement for new and more effective therapies and technologies which can prevent these 
diseases. The existing treatments for CVDs aim to restore the normal blood flow around the 
damaged vasculature and prevent recurring phenomenon. Banach et al. [49] suggested that by 
statin therapy, reduction in build-up and thickening of plaques can be achieved. However, such 
therapies also have adverse side effects and poor patient compliance, which suggests that 
modifications of such treatments are needed. This among other factors has accelerated the 
deployment of nanotechnology, (the leading area in 21st century sciences globally), in biomedicine 
and witnessed the birth of a new field, nanomedicine.  
 
3.1 Significance 
Nano-based drug delivery systems have great potential in the field of health care. They provide 
better penetration of drugs through the body as their size allows delivery via injection or other 
routes. The application of nanoscience in medicine aims to improve the existing treatment 
regarding these diseases [51]. Nanotechnology provides an effective and safe platform in 
controlled drug delivery systems for a range of active ingredients, which are directed to lipid 
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disorders, angiogenesis within atherosclerosis and inflammation and avoidance of thrombosis 
among other diseases [52]. Iron oxide super-paramagnetic nanoparticles are a major development 
in the magnetic drug targeting [53]. The magnetic drug targeted system provides appropriate 
magnetic gradients, which further increase the concentration of nanoparticles at the affected site 
[54].  
 
Figure 8: Nanoparticle flow, margination and adhesive properties in blood vessels depending on 
geometry and particle size [50] 
 




Nanoparticles can also enhance the delivery of anti-inflammatory agents i.e. glucocorticoids, 
which further reduce the macrophage accumulation in atherosclerotic lesions. Glucocorticoids 
have unfavorable profiles such as short half-life times and a large volume of distribution, which 
results in the necessity for frequent high doses and the associated unbearable side effects such as 
hypertension and diabetes. To overcome this problem, liposomal formulation is proposed, which 
prolongs the circulation time, resulting in marked improvement of drug accumulation in the 
endothelium [56]. For the treatment of atherosclerotic lesions, studies have been conducted using 
liposomes loaded with phosphatidyl-choline (PC). PC is a compound that increases the 
concentration of high-density lipoproteins and decreases LDL (low-density lipoprotein) oxidation 
in atherosclerotic plaque, thus limiting the inflammatory process occurring at this site. In the aortic 
wall, reduction in plaque volume and cholesterol has been reported after 5 weeks of treatment with 
liposomal formulation, which suggests that it can become an attractive therapy to reduce 
atherosclerotic plaques [57]. 
 
3.2 Nano-based Blood Flow (Nano-hemodynamic) Models 
The expansion of nanotechnology has revolutionized biomedicine in the 21st century. Many new 
nanomaterials have also been implemented in a variety of areas in biomechanics and biofluid 
mechanics. A sub-set of these nanomaterials (which include carbon nanotubes, nano shells, 
nanorods and nanowires) is nanofluids, mentioned earlier. Although initially developed for 
automotive and thermal power applications, nanofluids have been successfully utilized in an 
astonishing range of clinical applications. These have included both theoretical and experimental 
studies, largely based on the Buongiorno model [58] which is a two-component nanoscale 
formulation emphasizing Brownian motion and thermophoretic body force effects (originating in 
nuclear engineering at MIT) or the Tiwari-Das model [59] which is a volume-fraction-based 
doping model. Interesting uses of nanofluids in medicine include blood purification systems [60], 
smart bio-nano-polymer coatings for medical devices [61], nano-drug delivery (pharmacological 
systems) in cardiovascular treatment [62, 63], biodegradable nano-liquids for cerebral pharmaco-
dynamics [64], membrane oxygenator bioreactors [65], orthopaedic lubrication with nano-films 
(super-lubricated poly (3‐sulfopropyl methacrylate potassium salt)‐grafted mesoporous silica 
nanoparticles suspended in starch base liquids) [66],  pulsed laser ablation (PLA) ultra-pure silicon 
nanofluid fabrication for cancer therapy [67], smart biomimetic electro-osmotic nanofluid pumps 
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in ocular diagnosis [68], cryopreservation, bone reinforcement via super-paramagnetic nanofluids 
etc. In hemodynamic therapies, the base liquid is clearly blood and this may be doped with a variety 
of nanoparticles including gold. It has been discussed earlier in this review that in the field of 
nanomedicine, nanoparticles have been broadly studied as particular carriers since as drug delivery 
systems, they deliver excellent results as a result of their biocompatibility, subcellular size, 
decreased toxicity and sustained release properties. Many theoretical studies have been explored 
to illustrate the effect of various nanoparticles in blood flows and this area of study is known as 
nano-hemodynamics. In particular, stenotic nano-hemodynamics has witnessed considerable 
interest in the engineering sciences and applied mathematics communities owing to its significance 
in combatting diseased arteries. The many studies reported have also featured numerous 
computational methods which are required to tackle the nonlinearity of the mathematical models. 
Nadeem et al. [69] studied the steady blood flow through tapered stenosed arteries using 
nanoparticles with a Prandtl blood flow mode and a homotopy perturbation method. Akbar and 
Nadeem [70] explored the influence of nanoparticles in a two-dimensional uniform tube under 
peristaltic waves with a couple stress rheological model, showing that with increasing 
thermophoresis and Brownian motion parameters, blood temperature is increased. Ellahi et al. [71] 
presented a numerical study of composite steady-state stenotic nanofluid hemodynamic flow 
through vessels with permeable walls. Ahmed et al. [72] investigated the influence of different   
nanoparticles (Cu, TiO2, Al2O3) on Newtonian blood flow in a single stenosed vessel, noting that 
flow acceleration in the core region is greater for Al2O3 nanoparticles than either Cu or TiO2 
nanoparticles. Mekheimer et al. [73] considered the simultaneous effect of metallic nanoparticles 
(copper) and magnetic field on micropolar blood flow through an overlapping mildly stenotic 
artery, observing that under stronger magnetic field, with higher nanofluid volume fraction, the 
velocity and wall shear stress are elevated. Nadeem and Ijaz [74] explored the influence of single 
wall carbon nanotubes (SWCNT) on peristaltic hemodynamic characteristics in multiple stenotic 
arteries with variable nanofluid viscosity. They found that compared with the pure blood case, the 
size of the trapping bolus increases with an increment in nanoparticle concentration. Nadeem et. 
al. [75] studied the impact of different metallic nanoparticles in blood flow through an artery 
featuring both a stenosis and an aneurysm. Elnaqeeb et al. [76] presented a simulation for blood 
flow conveying copper nanoparticles through a catheterized single stenotic artery with thrombosis, 
noting that velocity is increased whereas hemodynamic resistance (impedance) is reduced with 
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greater nanoparticle volume fraction. Ahmed et al. [77] addressed the effect of nanoparticle shape 
factor on Newtonian blood flow in an overlapping (catheterized) stenotic artery for the case of 
copper nanoparticles, highlighting deviations in hemodynamic behaviour between curved and non-
curved arteries. Ijaz et al. [78] studied the influence of hybrid nanoparticles (silver, copper and 
gold) nanoparticles on blood flow characteristics in a stenotic channel, noting that gold 
nanoparticles exert a more dramatic impact. Changdar and De [79] have performed an analytical 
investigation of the effect of gold nanoparticles in magnetohydrodynamics (MHD) blood flow 
through an irregular shaped stenosed artery. They showed that velocity and displacement profiles 
exhibit greater fluctuations with smaller nanoparticles. Ponalagusamy et al. [80] described a 
theoretical viscoplastic blood flow model for unsteady nano-hemodynamics in a tapered single 
stenotic artery under the influence of magnetic field and periodic body acceleration, for the case 
of ferric oxide (Fe2O3) nanoparticles. Ijaz et al. [81] investigated the Cu and CuO nanoparticle-
mediated blood flow in an overlapped mildly stenotic artery, noting that wall shear stress and flow 
resistance decreases with platelet shaped nanoparticles. Ali et al. [82] performed a numerical 
simulation of time-dependent non-Newtonian (Sisko fluid) nano-pharmacodynamic transport 
phenomenon in an overlapping tapered artery using Buongiorno’s model and a forward time 
central space (FTCS) method. Results were validated with finite element method (FEM) and it was 
found that flow rate at stenotic throat decreases with an increase in the Brownian motion parameter. 
Zaman et al. [83] investigated the unsteady blood flow through a curved stenosed artery with an 
aneurysm for hybrid nanoparticles (copper, silver) also using the FTCS method. They observed 
that with greater nanoparticle volume fraction, flow rate, velocity and wall shear stress increases 
whereas the impedance is reduced. Ahmed et al. [84] considered 6 types of stenosis geometry and 
studied the effects of magnetohydrodynamic body force and hybrid nanoparticles (Cu and Al2O3) 
on electrically conducting micropolar nano-doped arterial blood flow. They noted that among all 
the stenosis geometries, maximum flow acceleration was computed for the trapezoidal type while 
maximum deceleration was associated with the irregular symmetric stenosis. Sultan et al. [85] 
used an Eyring-Powell viscoelastic nanofluid model to simulate time-dependent nano-
hemodynamic flow in a stenotic, aneurysmic and curved artery, noting that non-Newtonian blood 
attains higher velocities in the post-stenotic region compared with the stenotic zone. A number of 
other interesting studies related to application of nanoparticles in pharmacological hemodynamics 
have been communicated. Very recently, Vasu et al. [86] have developed a robust model of non-
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Newtonian nanofluid hemodynamics with heat and mass diffusion in a stenosed coronary artery in 
the presence of a radial magnetic field. The study provides a deeper understanding of nano-drug 
diffusion in the treatment of cardiovascular disease (stenotic arteries). Buongiorno’s nanoscale 
model and the Reiner-Rivlin second order differential model are employed in the formulation. The 
geometry considered in [86] is reproduced in Fig. 10.  
 
 
Figure 10.  Schematic illustration of stenosed coronary arterial model [86] 
 
The FreeFEM++ finite element code [87] was used to compute hemodynamic characteristics in 
this study. The finite element mesh was designed with 5928 unstructured fixed triangular elements 
with 12177 nodes as presented in Figure 11. The mesh generation was accomplished with the 
automatic FreeFEM++ mesh generator based on the Delaunay-Voronoi algorithm.  
 
 








Some selected simulations from [86] are shown in Figs. 12 a-d for non-dimensional velocity 
profile for different values of magnetic field parameter (M) and thermophoresis parameter ( tN ) is 
in the arterial domain, corresponding to the mild stenosis case (here the blood flow direction is 
taken from left to right). 
    
   12(a)      12(b) 
     
   12(c)      12(d) 
Figure 12 Velocity field (a) 0.3, 0.3 0.3b tM N and N= = =  (b) 0.3, 0.3 0.6b tM N and N= = = , 
(c) 0.6, 0.3 0.3b tM N and N= = = , (d) 0.6, 0.3 0.6b tM N and N= = =  [86]. 
 
Increasing the values of thermophoresis parameter (
tN ) from 0.3 to 0.6 (with magnetic parameter, M, 
and Brownian motion parameter, 
bN  fixed) decrease the value of velocity in the vessel. 
Thermophoresis relates to the migration of nanoparticles under the force of a temperature gradient. 
With nanoparticles migrating, the momentum is inhibited in the arterial flow and deceleration 
induced. Effectively thermophoretic body force arises due to the averaged Brownian motion of 
particles in the nano-doped blood under a steady temperature gradient. Since steady state conditions 
are assumed, the stronger molecular impulses in the hotter nanofluid region mobilize nanoparticles to 
migrate towards the colder region, where the molecular impulses are weaker. This destroys 
momentum in the blood flow and results in a depletion in velocity. In particular, in the core zone 
strong deceleration is induced. With increasing magnetic parameter (M) from 0.3 to 0.6 as shown in 
figures 12a and 12c (for 
tN  = 0.3) and figures 12b and 12d (for tN = 0.6) there is also a significant 
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decrement in velocity i.e. the core flow is again retarded. The presence of the Lorentzian magnetic 
drag force resists blood flow and especially generates deceleration in the constricted zone at the 
stenosis which in turn influences the remainder of the flow domain. In all plots, the velocity is 
maximum at centreline of the artery and decreases to the boundary at which it vanishes in accordance 
with the no-slip condition. Computational nano-hemodynamics clearly is a powerful tool for 
visualization in modern nano-biomedicine and drug delivery systems and provides an excellent 
methodology for optimizing the impact of different nano-drugs in clinical treatments. Other numerical 
methodologies are also very promising in this regard and include Lattice Boltzmann [89], molecular 




In the present review, recent advances in nanomedicine have been considered in addition to 
progress in the delivery of old drugs with new therapeutic methods. Initially, to enhance the 
solubility, bioavailability, absorption and targeted and controlled release of drugs is the main 
motivation for implementing nanotechnology in biomedicine. The use of nano- carriers formulated 
with dendrimers, liposomes, micelles, solid lipid nanoparticles, gold, silver, titanium oxide and 
cadmium sulphide polymeric nanoparticles together with superparamagnetic iron oxide 
nanoparticles has been shown to substantially improve the efficacy of conventional 
pharmacological agents. Magnetic drug delivery systems also offer excellent potential due to their 
unique properties which are ideal for targeted and controlled delivery. This review has also 
described significant progress in the use of mathematical and computational hemodynamic models 
for simulating nanoparticle drug delivery effects in cardiovascular diseases (stenotic arteries, 
aneurysms etc). Computational nano-hemodynamics offers great advantages in providing deeper 
insight into the inherent mechanisms involved in nano-drug delivery. Many methods have been 
developed in this regard and warrant further investigation and corroboration with clinical findings. 
The advancement in nano-biomedicine along with improved safety and reduced toxicity will be 
greatly accelerated with computational modelling techniques which are under continuous 
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